BACKGROUND: Quantification of triglyceride-rich lipoprotein (TRL) remnants is useful for risk assessment of coronary artery disease and the diagnosis of type III hyperlipoproteinemia. Although an immunoseparation procedure for remnant-like particle cholesterol has been evaluated extensively in recent years, available methods for measuring TRL remnants have not achieved wide use in routine laboratory practice, suggesting a need for a homogeneous assay that can measure TRL remnant cholesterol in serum or plasma without pretreatment. METHODS: We screened for suitable surfactants that exhibited favorable selectivity toward the VLDL remnant (VLDLR) fraction, including intermediate-density lipoproteins (IDLs). We investigated the principal characteristics of this assay by gel filtration of lipoproteins and their particle size distribution. We developed a simple assay and evaluated its performance with the Hitachi-7170 analyzer. RESULTS: Polyoxyethylene-polyoxybutylene block copolymer (POE-POB) exhibited favorable selectivity toward VLDLR and IDL fractions. POE-POB removed apolipoprotein (apo) E and apo C-III from IDL particles in the presence of cholesterol esterase (CHER), and the particle size distribution of IDLs became smaller after the reaction. These results revealed that IDL particles are specifically modified in the presence of CHER and POE-POB, making their component cholesterol available for enzymatic assay. Addition of phospholipase D improved the reactivity toward chylomicron remnants (CMRs). We found a high correlation [y = 1.018x- 0.01 mmol/L, r = 0.962 (n = 160)] between the proposed assay and the immunoseparation assay in serum from healthy individuals. CONCLUSION: The homogeneous assay described in this report can measure TRL remnant cholesterol, including CMRs, VLDLRs, and IDLs, with high sensitivity and specificity.
BACKGROUND: Quantification of triglyceride-rich lipoprotein (TRL) remnants is useful for risk assessment of coronary artery disease and the diagnosis of type III hyperlipoproteinemia. Although an immunoseparation procedure for remnant-like particle cholesterol has been evaluated extensively in recent years, available methods for measuring TRL remnants have not achieved wide use in routine laboratory practice, suggesting a need for a homogeneous assay that can measure TRL remnant cholesterol in serum or plasma without pretreatment. METHODS: We screened for suitable surfactants that exhibited favorable selectivity toward the VLDL remnant (VLDLR) fraction, including intermediate-density lipoproteins (IDLs). We investigated the principal characteristics of this assay by gel filtration of lipoproteins and their particle size distribution. We developed a simple assay and evaluated its performance with the Hitachi-7170 analyzer. RESULTS:Polyoxyethylene-polyoxybutylene block copolymer (POE-POB) exhibited favorable selectivity toward VLDLR and IDL fractions. POE-POB removed apolipoprotein (apo) E and apo C-III from IDL particles in the presence of cholesterol esterase (CHER), and the particle size distribution of IDLs became smaller after the reaction. These results revealed that IDL particles are specifically modified in the presence of CHER and POE-POB, making their component cholesterol available for enzymatic assay. Addition of phospholipase D improved the reactivity toward chylomicron remnants (CMRs). We found a high correlation [y = 1.018x- 0.01 mmol/L, r = 0.962 (n = 160)] between the proposed assay and the immunoseparation assay in serum from healthy individuals. CONCLUSION: The homogeneous assay described in this report can measure TRL remnant cholesterol, including CMRs, VLDLRs, and IDLs, with high sensitivity and specificity.
Authors: Seiko Otokozawa; Masumi Ai; Margaret R Diffenderfer; Bela F Asztalos; Akira Tanaka; Stefania Lamon-Fava; Ernst J Schaefer Journal: Metabolism Date: 2009-07-09 Impact factor: 8.694
Authors: Stefania Lamon-Fava; Margaret R Diffenderfer; P Hugh R Barrett; Aaron Buchsbaum; Mawuli Nyaku; Katalin V Horvath; Bela F Asztalos; Seiko Otokozawa; Masumi Ai; Nirupa R Matthan; Alice H Lichtenstein; Gregory G Dolnikowski; Ernst J Schaefer Journal: Arterioscler Thromb Vasc Biol Date: 2008-06-19 Impact factor: 8.311
Authors: Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef Journal: Arterioscler Thromb Vasc Biol Date: 2009-10-15 Impact factor: 8.311
Authors: Alan Chait; Henry N Ginsberg; Tomas Vaisar; Jay W Heinecke; Ira J Goldberg; Karin E Bornfeldt Journal: Diabetes Date: 2020-04 Impact factor: 9.461
Authors: Seiko Otokozawa; Masumi Ai; Thomas Van Himbergen; Bela F Asztalos; Akira Tanaka; Evan A Stein; Peter H Jones; Ernst J Schaefer Journal: Atherosclerosis Date: 2008-11-12 Impact factor: 5.162
Authors: Sonia Vega-López; Nirupa R Matthan; Lynne M Ausman; Scott V Harding; Todd C Rideout; Masumi Ai; Seiko Otokozawa; Alicia Freed; Jeffrey T Kuvin; Peter J Jones; Ernst J Schaefer; Alice H Lichtenstein Journal: Atherosclerosis Date: 2009-12-05 Impact factor: 5.162